Role of radiotherapy combined with Endostar in non-small cell lung cancer patients with brain metastasis and different EGFR mutations(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2026年第2期
- Page:
- 240-244
- Research Field:
- 医学生物物理
- Publishing date:
Info
- Title:
- Role of radiotherapy combined with Endostar in non-small cell lung cancer patients with brain metastasis and different EGFR mutations
- Author(s):
- MA Xiaoyun1; LI Quanfu2; JIN Gaowa2
- 1. Chifeng Clinical Medical College, Inner Mongolia Medical University, Chifeng 024000, China 2. Ordos Clinical Medical College, Inner Mongolia Medical University, Ordos 017000, China
- Keywords:
- Keywords: non-small cell lung cancer brain metastasis radiotherapy Endostar epidermal growth factor receptor gene mutation
- PACS:
- R816.1；R734.2
- DOI:
- DOI:10.3969/j.issn.1005-202X.2026.02.014
- Abstract:
- Abstract: Objective To investigate the application of radiotherapy combined with Endostar in patients with brain metastases from non-small cell lung cancer (NSCLC) harboring different epidermal growth factor receptor (EGFR) mutations. Methods Clinical data of patients with pathologically and radiologically confirmed brain metastases from NSCLC were collected. All patients received whole brain radiotherapy alone or in combination with stereotactic radiosurgery. Those with EGFR mutations detected through genetic testing were additionally administered oral TKI therapy. Concurrent endostatin (Endostar) treatment was given based on the severity of clinical manifestations related to brain metastases as well as the willingness of patients and their families. Changes in brain edema volume before and after treatment were compared, and overall survival (OS) was followed up. Results (1) The average brain edema volume was significantly reduced after radiotherapy in all patients. Among patients receiving Endostar combination treatment, the decrease in brain edema volume in the EGFR-mutant group after radiotherapy was significantly greater than that in the wild-type group, and the brain edema volume changes in EGFR-mutant group was statistically significant (P<0.05). In patients receiving treatment without Endostar, the decrease in brain edema volume after radiotherapy was more pronounced in the EGFR-mutant group than in the wild-type group, and a significant brain edema volume change was observed in the EGFR-mutant group (P<0.05). (2) The median OS of the patients receiving Endostar combination treatment versus those receiving treatment without Endostar was 31.4 months versus 15.9 months (P=0.029). The median OS of the EGFR-mutant group versus the wild-type group were 24.2 months versus 18.4 months (P=0.733). In EGFR-mutant patients, the median OS of those receiving Endostar combination treatment versus those receiving treatment without Endostar was 24.2 months versus 15.3 months, (P=0.09). (3) At the 1 month follow-up after treatment, among 11 patients receiving Endostar combination treatment, 6 cases achieved CR+PR, 4 cases showed SD, and 1 case had PD while in 14 patients receiving treatment without Endostar, there were 6 cases of CR+PR, 8 cases of SD, and 0 cases of PD. Conclusion The combination of radiotherapy and Endostar can improve the survival outcome of NSCLC patients with brain metastases.
Last Update: 2026-01-27